18:59:31 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-25 Ordinarie utdelning MEDI 4.50 NOK
2024-04-24 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-25 Kvartalsrapport 2023-Q1
2023-04-25 Ordinarie utdelning MEDI 4.50 NOK
2023-04-24 Årsstämma 2023
2023-03-01 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning MEDI 3.75 NOK
2022-04-27 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-10-22 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning MEDI 3.00 NOK
2021-04-27 Kvartalsrapport 2021-Q1
2021-04-27 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-10-22 Ordinarie utdelning MEDI 2.75 NOK
2020-08-14 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-04-28 Årsstämma 2020
2020-04-03 Extra Bolagsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-04-25 Ordinarie utdelning MEDI 2.25 NOK
2019-04-25 Kvartalsrapport 2019-Q1
2019-04-24 Årsstämma 2019
2019-03-15 Bokslutskommuniké 2018
2019-02-27 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-04-26 Ordinarie utdelning MEDI 2.00 NOK
2018-04-26 Kvartalsrapport 2018-Q1
2018-04-25 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning MEDI 1.75 NOK
2017-04-27 Kvartalsrapport 2017-Q1
2017-04-26 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-10-19 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-04-20 Ordinarie utdelning MEDI 1.65 NOK
2016-04-19 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-04-24 Ordinarie utdelning MEDI 1.40 NOK
2015-04-24 Kvartalsrapport 2015-Q1
2015-04-23 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-04-25 Kvartalsrapport 2014-Q1
2014-04-24 Ordinarie utdelning
2014-04-23 Årsstämma 2014
2014-02-20 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-20 Kvartalsrapport 2013-Q2
2013-04-26 Ordinarie utdelning
2013-04-25 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-08 Kapitalmarknadsdag 2013
2013-02-28 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-04-27 Kvartalsrapport 2012-Q1
2012-04-27 Ordinarie utdelning
2012-04-26 Årsstämma 2012
2012-02-22 Bokslutskommuniké 2011
2011-10-28 Kvartalsrapport 2011-Q3
2011-08-24 Kvartalsrapport 2011-Q2
2011-04-29 Ordinarie utdelning
2011-04-29 Kvartalsrapport 2011-Q1
2011-04-28 Årsstämma 2011
2011-02-18 Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Medistim är ett ultraljudsteknikföretag. Medistim utvecklar och kommersialiserar medicinsk utrustning för användning inom hjärt-, kärl- och transplantationskirurgi. Företaget strävar efter att minska risker och förbättra kvaliteten i sådana operationer genom att använda överföringstidsflödesmätning och högfrekvent ultraljudsavbildning. Medistim har dotterbolag och distributörer med försäljningsorganisationer på marknader runt om i världen. Kunderna är offentliga och privata sjukhus och företaget har sitt huvudkontor i Norge.
2021-01-05 08:35:29
(Oslo, 5th of January 2021) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarter in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery, announces that they have signed a Distributor Agreement with LivaNova
for distribution of Medistim products in India.

With its population size of about 1,4 billion, India is a large and emerging
market for Medistim's ultrasound devices. Today, about 100,000 coronary bypass
(CABG) procedures are performed in India annually, representing a market size of
about half of the USA. The disproportionally low number of procedures compared
to population size, as well as the growth in the general economy and health care
investments, are expected to drive higher growth in CABG procedures in this
market compared to the developed, western world. Hence, India is an important
market for Medistim's long term strategy and growth.

As the cost of a CABG procedure in India is significantly lower than in many
other markets , Medistim has a 2-tier product strategy in this market, offering
both a lower-priced entry-level flowmeter (SonoQ), as well as the high-end
portfolio with high frequency ultrasound imaging (HFUS) as an additional option
(MiraQ).
As of January 1st 2021, LivaNova will represent Medistim in India, through its
Cardiovascular business unit. LivaNova is a globally operating medical device
manufacturer with a strong foothold in cardiac surgery. They are a market
leader within heart-lung machines, hence targeting the same target customers as
Medistim's intraoperative ultrasound devices.

"LivaNova has already proven to be a strong partner for us in Australia, and we
are very excited to develop the business in India together as well," said
Medistim President and CEO, Kari E. Krogstad. "With their highly competent local
team and strong product synergies we should be perfectly positioned to build a
strong business over the years to come."

"We are pleased to be expanding our partnership with Medistim to now include
distribution in India" said Sujay Mashru, Vice President and Managing Director -
Asia Pacific of LivaNova. "This unique portfolio of products for surgical
guidance and blood flow measurement will strengthen our Cardiovascular business
in India and enable us to leverage our strong expertise in cardiac surgery to
grow the market".

About LivaNova:
LivaNova PLC is a global medical technology and innovation company built on
nearly five decades of experience and a relentless commitment to provide hope
for patients and their families through innovative medical technologies,
delivering life-changing improvements for both the Head and Heart. Headquartered
in London, LivaNova employs approximately 4,000 employees and has a presence in
more than 100 countries for the benefit of patients, healthcare professionals
and healthcare systems worldwide. For more information, please visit
www.livanova.com.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark
and Norway, in addition to the about 60 distributors in Europe, Asia, Middle
East, Africa, Canada and South America. For more information, visit the
Medistim home page: www.Medistim.com

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com